Stoke Therapeutics, Inc. (STOK)

Market Cap	1.93B +292.2%
Revenue (ttm)	32.08M -83.2%
Net Income	-169.77M
EPS	-2.81
Shares Out	62.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	543,779
Open	31.93
Previous Close	31.61
Day's Range	30.66 - 31.94
52-Week Range	9.34 - 40.22
Beta	1.20
Analysts	Strong Buy
Price Target	45.10 (+45.91%)
Earnings Date	May 7, 2026

About STOK

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2019
• Employees: 170
• Stock Exchange: NASDAQ
• Ticker Symbol: STOK
• Website: https://www.stoketherapeutics.com

Financial Performance

In 2025, Stoke Therapeutics's revenue was $184.42 million, an increase of 404.50% compared to the previous year's $36.56 million. Losses were -$6.89 million, -92.26% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price target is $45.1, which is an increase of 45.91% from the latest price.

Price Target

$45.1

(45.91% upside)

Analyst Consensus: Strong Buy